Nekon Bio

Neion Bio is a private biotechnology company focused on reinventing biologics manufacturing rather than advancing a traditional proprietary therapeutic pipeline. The company uses genetic engineering and stem cell biology to turn eggs into bioreactors for the production of recombinant biologics, including monoclonal antibodies, enzymes, fusion proteins, peptides, cytokines, and other therapeutic proteins. Its Raptor platform is designed to lower biologics manufacturing costs, improve consistency, reduce capital intensity, and support more localized and resilient supply chains. In March 2026, the company emerged from stealth, announced an $11 million seed financing, and disclosed its first co-development and supply agreement with a major global pharmaceutical company covering up to three monoclonal antibodies. Neion Bio appears best characterized as a platform biomanufacturing company serving biopharma partners, with early commercial activity but no publicly disclosed in-house clinical assets.